ClinicalTrials.gg
CompletedNCT02093897Updated Jan 27, 2017Results posted

Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A

A Phase 3 interventional study of rVIII-SingleChain in Congenital Hemophilia A, sponsored by CSL Behring. Completed at 37 sites in 19 countries. Open to male participants aged Up to 11 Years. Per ClinicalTrials.gov, last updated 2017-01-27.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
Up to 11 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Hemophilia A by CSL Limited — none open to participants now, none under way, none of them phase 3. Hemophilia A · CSL Limited.

Enrollment
3rd of 11
84 · median 62
Started
2014
with 1 other
Phase 3
6 of 14
none open now
Registered
8th of 14
by date

Among the 14 studies in Hemophilia A by CSL Limited, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2014, is one of 6 in phase 3, and was the 8th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

None of the 14 studies in Hemophilia A by CSL Limited is open now. The open studies under Hemophilia A, anywhere →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: Up to 11 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Hemophilia A by CSL Limited as a file.
02

Study summary

This is an international, multicenter, open-label study to assess the efficacy, safety, and pharmacokinetic (PK) profile of rVIII-SingleChain in pediatric patients with severe hemophilia A. A minimum of 25 previously treated subjects ≥ 6 to \< 12 years of age and at least 25 subjects \< 6 years of age who have undergone > 50 exposure days (EDs) with a previous Factor VIII (FVIII) product are planned to be enrolled. Subjects will be assigned to either an on-demand or prophylaxis treatment regimen and will receive rVIII-SingleChain at a dose to be determined by the investigator. Hemostatic efficacy will be assessed by the subject/caregiver and the investigator who will assess overall efficacy by a 4-point scale.

03

Conditions studied

  • Congenital Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
Up to 11 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of severe hemophilia A defined as \< 1% Factor VIII (FVIII) concentration (FVIII:C) documented in medical records,
  • Males \< 12 years of age,
  • Subjects who have received > 50 EDs with a FVIII product,
  • Prior PK data (at least incremental recovery and half-life) from previous FVIII exposure for subjects participating in the PK part
  • Investigator believes that the subject is willing and able to adhere to all protocol requirements. Investigator believes that the subject's parent(s) or legally acceptable representative(s) is / are willing and able to adhere to all protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Any history of or current FVIII inhibitors
  • Use of an Medical Product (IMP) within 30 days prior to the first rVIII-SingleChain administration,
  • Administration of any cryoprecipitate, whole blood or plasma within 30 days prior to administration of rVIII-SingleChain,
  • Known (allergic reaction or anaphylaxis) to any FVIII product or hamster protein,
  • Subject currently receiving IV immunomodulating agents such as immunoglobulin or chronic systemic treatment,
  • Subject with serum (AST) or serum alanine aminotransferase (ALT) values >5 times (x) the (ULN) at Screening,
  • Subjects with serum creatinine values >2 x ULN at Screening,
  • Evidence of thrombosis, including deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction and arterial embolus within 3 months before Day 1,
  • Experienced life-threatening bleeding episode or had major surgery or an orthopedic surgical procedure during the 3 months before rVIII-SingleChain administration.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    rVIII-SingleChain

    Subjects will be assigned to either an on-demand or prophylaxis regimen and will receive rVIII-SingleChain as an intravenous (IV) infusion. Subjects assigned to a prophylaxis regimen will be treated with 15 to 50 IU/kg of rVIII-SingleChain every second day or 2 to 3 times per week, or at the investigator's discretion, based on available PK data, the FVIII treatment regimen used before enrollment and/or the subject's bleeding phenotype. The dose for on-demand treatment of a bleeding episode is based on the recommendations of the World Federation of Hemophilia (WFH), with a minimum dose of 15 IU/kg. All subjects were to be treated for a minimum of 50 EDs. For the PK evaluation, the subjects will receive a single IV dose of 50 IU/kg of rVIII-SingleChain on Day 1 at the start of the PK evaluation period.

    Biological: rVIII-SingleChain

Interventions

  • Also known as: Recombinant Factor VIII single chain, CSL627

06

What researchers measure

Primary outcomes

  1. Treatment Success

    Rate of treatment success where treatment success of a bleeding episode is defined as a rating of "excellent" or "good" based on the investigator's overall clinical assessment of hemostatic efficacy (using a 4-point scale of excellent, good, moderate or poor/no response) on the on-demand and prophylaxis regimens combined. The rate of success was based on the number of treated bleeding events; there were 347 treated bleeding events in the Efficacy Population.

    Time frame: Up to 1 year

Secondary outcomes

  1. Annualized Bleeding Rate

    The annualized bleeding rate was defined as the number of bleeding episodes requiring treatment divided by the efficacy evaluation period in days, x 365.25, and is presented separately for the on-demand regimen and the prophylaxis regimens.

    Time frame: Up to 1 year

  2. Percentage of Bleeding Episodes Requiring 1, 2, 3, or More Than 3 Infusions of rVIII-SingleChain to Achieve Hemostasis.

    Time frame: Up to 1 year

  3. Consumption of rVIII-SingleChain - IU/kg Per Subject Per Month

    Time frame: Up to 1 year

  4. Consumption of rVIII-SingleChain - IU/kg Per Subject Per Year

    Time frame: Up to 1 year

  5. Consumption of rVIII-SingleChain - IU/kg Per Bleeding Event

    Time frame: Up to 1 year

  6. Consumption of rVIII-SingleChain (On-demand Regimen) - Number of Infusions Per Subject Per Month

    Time frame: Up to 1 year

  7. Consumption of rVIII-SingleChain (On-demand Regimen) - Number of Infusions Per Subject Per Year

    Time frame: Up to 1 year

  8. Incremental Recovery

    Incremental recovery expressed as (IU/dL)/(IU/kg) corrected for subject's predose plasma FVIII activity measured using the chromogenic substrate assay.

    Time frame: At 1 hour after the start of infusion

  9. Half-life (t1/2) of rVIII-SingleChain

    Half-life (t1/2) of rVIII-SingleChain, baseline uncorrected; plasma FVIII activity measured using the chromogenic substrate assay.

    Time frame: Immediately before dosing, and at approximately 1, 5, 10, 24, and 48 hours after dosing.

  10. Area Under the Concentration Curve (AUC)

    AUC to the last sample with quantifiable drug concentration (AUC0-t), baseline uncorrected; plasma FVIII activity measured using the chromogenic substrate assay.

    Time frame: Immediately before dosing, and at approximately 1, 5, 10, 24, and 48 hours after dosing.

  11. Clearance (Cl) of rVIII-SingleChain

    Clearance (Cl) of rVIII-SingleChain, baseline uncorrected; plasma FVIII activity measured using the chromogenic substrate assay.

    Time frame: Immediately before dosing, and at approximately 1, 5, 10, 24, and 48 hours after dosing.

  12. Number of Subjects With Inhibitor Formation to rVIII-SingleChain

    The number of subjects who develop inhibitors to rVIII-SingleChain, defined as a rVIII-SingleChain antibody titer of at least 0.6 Bethesda Units (BU) per mL after receiving study drug.

    Time frame: At screening, then after dosing at approximately monthly intervals for 6 months, then every 3 months until reaching 50 EDs, and at the end of study visit (up to approximately 12 months).

07

Results

Posted Jan 27, 2017

Participant flow

This multicenter, multinational study enrolled subjects at 37 participating study centers in Australia, Europe, Georgia, Lebanon, Malaysia, Philippines, Switzerland, Thailand, Turkey, Ukraine, and the United States.

Participant flow — Overall Study
MilestonerVIII-SingleChain
Started84
Completed65
Not completed19
Withdrew: Physician decision1
Withdrew: Planned age group closure - no's reached17
Withdrew: Adverse event, non-fatal1

Outcome measures

PrimaryTreatment Success

Rate of treatment success where treatment success of a bleeding episode is defined as a rating of "excellent" or "good" based on the investigator's overall clinical assessment of hemostatic efficacy (using a 4-point scale of excellent, good, moderate or poor/no response) on the on-demand and prophylaxis regimens combined. The rate of success was based on the number of treated bleeding events; there were 347 treated bleeding events in the Efficacy Population.

Time frame:
Up to 1 year
Reported as:
Number · Percentage of treated bleeding events
Treatment Success
Percentage of treated bleeding eventsEfficacy Population
Treatment Success96.3 (91.3 to 98.4)
SecondaryAnnualized Bleeding Rate

The annualized bleeding rate was defined as the number of bleeding episodes requiring treatment divided by the efficacy evaluation period in days, x 365.25, and is presented separately for the on-demand regimen and the prophylaxis regimens.

Time frame:
Up to 1 year
Reported as:
Median · Treated bleeding episodes per year
Annualized Bleeding Rate
Treated bleeding episodes per yearOn-demandProphylaxis
Annualized Bleeding Rate78.56 (35.12 to 86.62)3.69 (0.00 to 7.20)
SecondaryPercentage of Bleeding Episodes Requiring 1, 2, 3, or More Than 3 Infusions of rVIII-SingleChain to Achieve Hemostasis.
Time frame:
Up to 1 year
Reported as:
Number · Percentage (%) of bleeding episodes
Percentage of Bleeding Episodes Requiring 1, 2, 3, or More Than 3 Infusions of rVIII-SingleChain to Achieve Hemostasis.
Percentage (%) of bleeding episodesEfficacy Population
Requiring 1 infusion85.9
Requiring 2 infusions9.8
Requiring 3 infusions2.3
Requiring > 3 infusions2.0
SecondaryConsumption of rVIII-SingleChain - IU/kg Per Subject Per Month
Time frame:
Up to 1 year
Reported as:
Median · IU/kg per subject per month
Consumption of rVIII-SingleChain - IU/kg Per Subject Per Month
IU/kg per subject per monthOn-demandProphylaxis
Consumption of rVIII-SingleChain - IU/kg Per Subject Per Month202 (126 to 231)378 (153 to 1394)
SecondaryConsumption of rVIII-SingleChain - IU/kg Per Subject Per Year
Time frame:
Up to 1 year
Reported as:
Median · IU/kg per subject per year
Consumption of rVIII-SingleChain - IU/kg Per Subject Per Year
IU/kg per subject per yearOn-demandProphylaxis
Consumption of rVIII-SingleChain - IU/kg Per Subject Per Year2429 (1508 to 2771)4541 (1839 to 16727)
SecondaryConsumption of rVIII-SingleChain - IU/kg Per Bleeding Event
Time frame:
Up to 1 year
Reported as:
Median · IU/kg per event
Consumption of rVIII-SingleChain - IU/kg Per Bleeding Event
IU/kg per eventOn-demandProphylaxis
Consumption of rVIII-SingleChain - IU/kg Per Bleeding Event25.9 (21 to 78)37.0 (16 to 282)
SecondaryConsumption of rVIII-SingleChain (On-demand Regimen) - Number of Infusions Per Subject Per Month
Time frame:
Up to 1 year
Reported as:
Median · number of infusion per subject per month
Consumption of rVIII-SingleChain (On-demand Regimen) - Number of Infusions Per Subject Per Month
number of infusion per subject per monthOn-demand
Consumption of rVIII-SingleChain (On-demand Regimen) - Number of Infusions Per Subject Per Month7.58 (5.1 to 7.7)
SecondaryConsumption of rVIII-SingleChain (On-demand Regimen) - Number of Infusions Per Subject Per Year
Time frame:
Up to 1 year
Reported as:
Median · number of infusions per subject per year
Consumption of rVIII-SingleChain (On-demand Regimen) - Number of Infusions Per Subject Per Year
number of infusions per subject per yearOn-demand
Consumption of rVIII-SingleChain (On-demand Regimen) - Number of Infusions Per Subject Per Year90.95 (60.9 to 92.3)
SecondaryIncremental Recovery

Incremental recovery expressed as (IU/dL)/(IU/kg) corrected for subject's predose plasma FVIII activity measured using the chromogenic substrate assay.

Time frame:
At 1 hour after the start of infusion
Reported as:
Mean · (IU/dL)/(IU/kg)
Incremental Recovery
(IU/dL)/(IU/kg)Pharmacokinetic Population
Incremental Recovery1.63 ± 0.329
SecondaryHalf-life (t1/2) of rVIII-SingleChain

Half-life (t1/2) of rVIII-SingleChain, baseline uncorrected; plasma FVIII activity measured using the chromogenic substrate assay.

Time frame:
Immediately before dosing, and at approximately 1, 5, 10, 24, and 48 hours after dosing.
Reported as:
Mean · hour
Half-life (t1/2) of rVIII-SingleChain
hourPharmacokinetic Population
Half-life (t1/2) of rVIII-SingleChain10.3 ± 2.51
SecondaryArea Under the Concentration Curve (AUC)

AUC to the last sample with quantifiable drug concentration (AUC0-t), baseline uncorrected; plasma FVIII activity measured using the chromogenic substrate assay.

Time frame:
Immediately before dosing, and at approximately 1, 5, 10, 24, and 48 hours after dosing.
Reported as:
Mean · IU*h/dL
Area Under the Concentration Curve (AUC)
IU*h/dLPharmacokinetic Population
Area Under the Concentration Curve (AUC)1050 ± 286
SecondaryClearance (Cl) of rVIII-SingleChain

Clearance (Cl) of rVIII-SingleChain, baseline uncorrected; plasma FVIII activity measured using the chromogenic substrate assay.

Time frame:
Immediately before dosing, and at approximately 1, 5, 10, 24, and 48 hours after dosing.
Reported as:
Mean · mL/h/kg
Clearance (Cl) of rVIII-SingleChain
mL/h/kgPharmacokinetic Population
Clearance (Cl) of rVIII-SingleChain4.86 ± 1.43
SecondaryNumber of Subjects With Inhibitor Formation to rVIII-SingleChain

The number of subjects who develop inhibitors to rVIII-SingleChain, defined as a rVIII-SingleChain antibody titer of at least 0.6 Bethesda Units (BU) per mL after receiving study drug.

Time frame:
At screening, then after dosing at approximately monthly intervals for 6 months, then every 3 months until reaching 50 EDs, and at the end of study visit (up to approximately 12 months).
Reported as:
Number · participants
Number of Subjects With Inhibitor Formation to rVIII-SingleChain
participantsrVIII-SingleChain
Number of Subjects With Inhibitor Formation to rVIII-SingleChain0

Adverse events

Collected over For the duration of the study, approximately 1 year, 5 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rVIII-SingleChain—9/84 (10.7%)31/84 (36.9%)
Most frequent serious events
Most frequent serious events
EventrVIII-SingleChain
Hand fractureInjury, poisoning and procedural complications1/84
LacerationInjury, poisoning and procedural complications1/84
Splenic ruptureInjury, poisoning and procedural complications1/84
Inhibiting antibodies positiveInvestigations1/84
AnaemiaBlood and lymphatic system disorders1/84
Device occlusionGeneral disorders1/84
Systemic inflammatory response syndromeGeneral disorders1/84
DyspepsiaGastrointestinal disorders1/84
BacteraemiaInfections and infestations1/84
PneumoniaInfections and infestations1/84
Most frequent other events
Most frequent other events
EventrVIII-SingleChain
NasopharyngitisInfections and infestations14/84
ArthralgiaMusculoskeletal and connective tissue disorders8/84
CoughRespiratory, thoracic and mediastinal disorders7/84
HeadacheNervous system disorders7/84
Head injuryInjury, poisoning and procedural complications5/84
PyrexiaGeneral disorders5/84

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)rVIII-SingleChain
<=18 years84
Between 18 and 65 years0
>=65 years0
Age, Continuous
Age, Continuous(years)rVIII-SingleChain
Mean6.6 ± 3.11
Gender
Gender(Participants)rVIII-SingleChain
Female0
Male84
Type of FVIII product used before enrollment
Type of FVIII product used before enrollment(participants)rVIII-SingleChain
Plasma product33
Recombinant Product49
Unknown2
Treatment modality of FVIII therapy before enrollment
Treatment modality of FVIII therapy before enrollment(participants)rVIII-SingleChain
Prophylaxis60
On-Demand24
08

Study locations

37 sites
  • Study Site
    Aurora, Colorado 80045, United States
  • Study Site
    Chicago, Illinois 60612, United States
  • Study Site
    Melbourne, Victoria 3052, Australia
  • Study Site
    Linz, 4020, Austria
  • Study Site
    Vienna, 1090, Austria
  • Study Site
    Brest, 29609, France
  • Study Site
    Le Kremlin Bicetre, 94270, France
  • Study Site
    Lille Cedex, 59037, France
  • Study Site
    Nantes, 44093, France
  • Study Site
    Paris, 75015, France
  • Study Site
    Tbilisi, 0177, Georgia
  • Study Site
    Bonn, 53127, Germany
  • Study Site
    Bremen, 28177, Germany
  • Study Site
    Frankfurt/Main, 60590, Germany
  • Study Site
    Hannover, 30159, Germany
  • Study Site
    Milano, 20122, Italy
  • Study Site
    Beirut, 11072240, Lebanon
  • Study Site
    Kuala Lumpur, 50400, Malaysia
  • Study Site
    Amsterdam, 1105 AZ, Netherlands
  • Study Site
    Njmegen, 6525 GA, Netherlands
  • Study Site
    Utrecht, 3584 CX, Netherlands
  • Study Site
    Cebu City, 6000, Philippines
  • Study Site
    Davao City, 8000, Philippines
  • Study Site
    Rzeszow, 35-310, Poland
  • Study Site
    Oporto, 4202-451, Portugal
  • Study Site
    Timisoara, 300011, Romania
  • Study Site
    Madrid, 28046, Spain
  • Study Site
    Lucerne, 6000, Switzerland
  • Study Site
    Bangkok, 10330, Thailand
  • Study Site
    Bangkok, 10700, Thailand
  • Study Site
    Chiang Mai, 50200, Thailand
  • Study Site
    Khon Kaen, 40002, Thailand
  • Study Site
    Songkla, 90110, Thailand
  • Study Site
    Adana, 01330, Turkey
  • Study Site
    Istanbul, 34098, Turkey
  • Study Site
    Izmir, 35100, Turkey
  • Study Site
    Lviv, 79044, Ukraine
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2014
First posted
Mar 21, 2014
Start
Mar 2014
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results first posted
Jan 27, 2017
Last update
Jan 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02093897
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Mar 21, 2014
Start date
Mar 2014
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Jan 27, 2017
Last update
Jan 27, 2017

Study contacts

Program Director
study director · CSL Behring

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lonoctocog alfa

Start the discussion